{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:34:02Z","timestamp":1778182442749,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.esmoop.2025.105857","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:24:27Z","timestamp":1761751467000},"page":"105857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Negative hyperselection of patients with stage III colon cancer receiving anti-EGFR-based adjuvant treatment"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4131-2409","authenticated-orcid":false,"given":"M.","family":"Ambrosini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0572-8426","authenticated-orcid":false,"given":"H.","family":"Blons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Garinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mulot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Le Corre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8950-1949","authenticated-orcid":false,"given":"S.","family":"Mouillet-Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3545-5518","authenticated-orcid":false,"given":"M.","family":"Sroussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9211-4707","authenticated-orcid":false,"given":"C.","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8475-5459","authenticated-orcid":false,"given":"P.","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9955-4753","authenticated-orcid":false,"given":"J.","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.esmoop.2025.105857_bib1","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105857_bib2","author":"Benson"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105857_bib3","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105857_bib4","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andr\u00e9","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105857_bib5","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","article-title":"Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial","volume":"13","author":"de Gramont","year":"2012","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105857_bib6","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S1470-2045(16)30172-3","article-title":"Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial","volume":"17","author":"Kerr","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105857_bib7","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(14)70227-X","article-title":"Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial","volume":"15","author":"Taieb","year":"2014","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105857_bib8","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2012.385","article-title":"Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial","volume":"307","author":"Alberts","year":"2012","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105857_bib9","first-page":"100","article-title":"Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147","volume":"13","author":"Huang","year":"2014","journal-title":"Clin Colorectal Cancer"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105857_bib10","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.2008.21.6663","article-title":"Randomized phase III trial comparing biweekly infusional fluorouracil\/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3","volume":"27","author":"Van","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105857_bib11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/annonc\/mdn680","article-title":"A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02\/FFCD9802)","volume":"20","author":"Ychou","year":"2009","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105857_bib12","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1200\/JCO.2007.11.2144","article-title":"Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803","volume":"25","author":"Saltz","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105857_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105857_bib14","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105857_bib15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105857_bib16","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105857_bib17","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1158\/2159-8290.CD-14-0462","article-title":"Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution","volume":"4","author":"Misale","year":"2014","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105857_bib18","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105857_bib19","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.22.01420","article-title":"FOLFOXIRI plus cetuximab or bevacizumab as first-Line treatment of BRAFV600E-mutant metastatic colorectal cancer: the randomized phase II FIRE-4.5 (AIO KRK0116) study","volume":"41","author":"Stintzing","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105857_bib20","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1200\/JCO.18.01798","article-title":"Mutational analysis of patients with colorectal cancer in CALGB\/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome","volume":"37","author":"Innocenti","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105857_bib21","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1093\/annonc\/mdx546","article-title":"Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study","volume":"28","author":"Cremolini","year":"2017","journal-title":"Ann Oncol"},{"issue":"33","key":"10.1016\/j.esmoop.2025.105857_bib22","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1200\/JCO.19.01254","article-title":"Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy","volume":"37","author":"Morano","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105857_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113396","article-title":"Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU\/LV","volume":"195","author":"Pietrantonio","year":"2023","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105857_bib24","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","article-title":"Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105857_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104511","article-title":"Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial","volume":"10","author":"Ciardiello","year":"2025","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105857_bib26","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/annonc\/mdw687","article-title":"Adjuvant FOLFOX +\/\u2212 cetuximab in full RAS and BRAF wildtype stage III colon cancer patients","volume":"28","author":"Taieb","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105857_bib27","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1200\/JCO.20.01600","article-title":"Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials","volume":"39","author":"Cohen","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105857_bib28","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.5225","article-title":"Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab","volume":"2","author":"Taieb","year":"2016","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105857_bib29","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1053\/j.gastro.2024.10.046","article-title":"ERBB2 comprehensive profiling and prognostication in Stage III Colon Cancer: findings from PETACC8 and IDEA-France cohorts","volume":"168","author":"Pilati","year":"2025","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105857_bib30","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1200\/JCO.23.02262","article-title":"Prognostic models from transcriptomic signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA-France trials","volume":"43","author":"Gallois","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105857_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2020.02.009","article-title":"Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: results of the DATECAN initiative","volume":"130","author":"Cohen","year":"2020","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105857_bib32","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.annonc.2023.08.006","article-title":"Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT\/IDEA pooled analysis of seven trials","volume":"34","author":"Taieb","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105857_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.582","article-title":"513MO Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: results from OrigAMI-1, an open-label, phase Ib\/II study","volume":"35","author":"Pietrantonio","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105857_bib34","doi-asserted-by":"crossref","first-page":"411","DOI":"10.6004\/jnccn.2017.0038","article-title":"Right versus left colon cancer biology: integrating the consensus molecular subtypes","volume":"15","author":"Lee","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105857_bib35","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00037","article-title":"Negative Ultraselection of patients with RAS \/ BRAF wild-type, microsatellite-stable metastatic colorectal cancer receiving anti-EGFR-based therapy","author":"Randon","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105857_bib36","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.22.00046","article-title":"Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial","volume":"41","author":"Morton","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105857_bib37","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.annonc.2024.12.013","article-title":"Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population","volume":"36","author":"Seligmann","year":"2025","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105857_bib38","article-title":"A biomarker enrichment trial of anti-EGFR agents in right primary tumor location (rPTL), RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC): ARIEL (ISRCTN11061442)","volume":"40","author":"Williams","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:08:21Z","timestamp":1764302901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2059702925017260"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105857","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Negative hyperselection of patients with stage III colon cancer receiving anti-EGFR-based adjuvant treatment","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105857"}}